Skip to main content

Table 3 Cardiac output expressed in l/min in the three study groups

From: Acute hypervolemic hemodilution combined with controlled hypotension to minimize blood loss during operations of spine fusion: remifentanil versus magnesium sulfate

 

Group I

(N = 18)

Group II

(N = 20)

Group III

(N = 19)

p value

Baseline

4.43 ± 1.14

4,52 ± 1.32

4.48 ± 1.21

0.820

5 min after start of AHH

5.21 ± 1.17

4.61 ± 1.18

4.58 ± 1.32

0.124

10 min after start of AHH

5.56 ± 1.32

4.67 ± 1.35*

4.63 ± 1.31*

0.038

15 min after start AHH

5.87 ± 1.31

4.71 ± 1.46*

4.67 ± 1.47*

0.013

30 min after start AHH

5.81 ± 1.21

4.78 ± 1.15*

4.72 ± 1.16*

0.008

45 min after start of AHH

5.52 ± 1.15

4.63 ± 1.31*

4.67 ± 1.08*

0.026

60 min after start of AHH

5.32 ± 1.12

4.51 ± 1.21*

4.56 ± 1.11*

0.042

90 min after start of AHH

5.31 ± 1.22

4.83 ± 1.21

4.72 ± 1.12

0.134

2 h after start of AHH

5.24 ± 1.13

4.42 ± 1.05

4.69 ± 1.36

0.026

3 h after start of AHH

5.11 ± 1.18

4.52 ± 1.17

4.58 ± 1.21

0.130

  1. -Data are presented as mean ± SD. p < 0.05 is considered significant.
  2. *Significant in group II or group III in relation to group I.